Danaher Co. (NYSE:DHR) Shares Sold by Yousif Capital Management LLC

Yousif Capital Management LLC lessened its stake in Danaher Co. (NYSE:DHR) by 2.9% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 81,892 shares of the conglomerate’s stock after selling 2,484 shares during the period. Yousif Capital Management LLC’s holdings in Danaher were worth $18,945,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Nicholas Hoffman & Company LLC. lifted its stake in shares of Danaher by 2.3% during the fourth quarter. Nicholas Hoffman & Company LLC. now owns 1,899 shares of the conglomerate’s stock worth $439,000 after purchasing an additional 43 shares in the last quarter. Drive Wealth Management LLC lifted its position in Danaher by 3.1% during the 4th quarter. Drive Wealth Management LLC now owns 1,485 shares of the conglomerate’s stock worth $344,000 after acquiring an additional 44 shares in the last quarter. Trust Investment Advisors boosted its holdings in Danaher by 1.8% in the 4th quarter. Trust Investment Advisors now owns 2,811 shares of the conglomerate’s stock worth $650,000 after acquiring an additional 49 shares during the period. New Hampshire Trust grew its position in Danaher by 0.3% in the third quarter. New Hampshire Trust now owns 14,438 shares of the conglomerate’s stock valued at $3,582,000 after acquiring an additional 50 shares in the last quarter. Finally, Connolly Sarah T. raised its stake in shares of Danaher by 0.5% during the third quarter. Connolly Sarah T. now owns 9,599 shares of the conglomerate’s stock valued at $2,382,000 after purchasing an additional 50 shares during the period. 79.05% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Danaher

In related news, SVP Daniel Raskas sold 23,757 shares of Danaher stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $252.00, for a total value of $5,986,764.00. Following the sale, the senior vice president now directly owns 38,102 shares in the company, valued at approximately $9,601,704. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, SVP Daniel Raskas sold 23,757 shares of the firm’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $252.00, for a total value of $5,986,764.00. Following the sale, the senior vice president now directly owns 38,102 shares in the company, valued at approximately $9,601,704. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Teri List sold 3,289 shares of the business’s stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total value of $816,724.48. Following the transaction, the director now owns 19,726 shares of the company’s stock, valued at approximately $4,898,360.32. The disclosure for this sale can be found here. Over the last quarter, insiders sold 32,957 shares of company stock worth $8,265,802. Insiders own 10.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a report on Wednesday, January 31st. KeyCorp raised their price objective on Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a research note on Thursday, February 1st. Royal Bank of Canada upped their target price on Danaher from $254.00 to $282.00 and gave the company an “outperform” rating in a research report on Wednesday, January 31st. Citigroup raised their price target on shares of Danaher from $255.00 to $280.00 and gave the stock a “buy” rating in a research report on Wednesday, January 31st. Finally, Barclays upped their price target on shares of Danaher from $240.00 to $260.00 and gave the company an “equal weight” rating in a report on Wednesday, April 10th. Six investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $268.27.

Danaher Stock Performance

Shares of NYSE:DHR traded up $17.03 during trading on Tuesday, reaching $253.11. 6,876,631 shares of the company’s stock traded hands, compared to its average volume of 2,777,720. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.68 and a quick ratio of 1.37. The company has a 50 day moving average of $248.95 and a 200-day moving average of $230.64. Danaher Co. has a 12 month low of $182.09 and a 12 month high of $259.00. The stock has a market capitalization of $187.44 billion, a P/E ratio of 39.61, a price-to-earnings-growth ratio of 3.95 and a beta of 0.83.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, January 30th. The conglomerate reported $2.09 earnings per share for the quarter, topping analysts’ consensus estimates of $1.91 by $0.18. The business had revenue of $6.41 billion for the quarter, compared to analysts’ expectations of $6.10 billion. Danaher had a return on equity of 12.25% and a net margin of 17.26%. The business’s quarterly revenue was down 10.2% on a year-over-year basis. During the same period in the prior year, the firm earned $2.87 EPS. On average, equities analysts expect that Danaher Co. will post 7.62 EPS for the current year.

Danaher Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, April 26th. Stockholders of record on Thursday, March 28th will be issued a dividend of $0.27 per share. This is an increase from Danaher’s previous quarterly dividend of $0.24. The ex-dividend date is Wednesday, March 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.43%. Danaher’s payout ratio is 16.90%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.